

Singapore

Population 2018

5.8 million

Estimates of TB burden ^o , 2018	Number (thousands)	Rate (per 100 000 population)
Total TB incidence	2.7 (2.3–3.1)	47 (40–54)
HIV-positive TB incidence	0.035 (0.022–0.05)	0.6 (0.39–0.87)
MDR/RR-TB incidence ^{oo}	0.046 (0.027–0.071)	0.81 (0.47–1.2)
HIV-negative TB mortality	0.051 (0.037–0.067)	0.89 (0.64–1.2)
HIV-positive TB mortality	<0.01 (<0.01–<0.01)	0.09 (0.05–0.15)

Estimated proportion of TB cases with MDR/RR-TB, 2018

New cases	1.6%
Previously treated cases	3.5% (0.73–9.9)

TB case notifications, 2018

Total new and relapse	2 331
- % tested with rapid diagnostics at time of diagnosis	60%
- % with known HIV status	89%
- % pulmonary	85%
- % bacteriologically confirmed ^{ooo}	62%
- % children aged 0-14 years	<1%
- % women	39%
- % men	61%
Total cases notified	2 334

Universal health coverage and social protection

TB treatment coverage (notified/estimated incidence), 2018	87% (75–100)
TB patients facing catastrophic total costs	
TB case fatality ratio (estimated mortality/estimated incidence), 2018	2% (1–3)

TB/HIV care in new and relapse TB patients, 2018

	Number	(%)
Patients with known HIV status who are HIV-positive	27	1%
- on antiretroviral therapy		

Drug-resistant TB care, 2018

% of bacteriologically confirmed TB cases tested for rifampicin resistance ^{ooo}	
- New cases	98%
- Previously treated cases	98%
Laboratory-confirmed cases*	MDR/RR-TB: 22, XDR-TB: 0
Patients started on treatment**	MDR/RR-TB: 15, XDR-TB: 0
MDR/RR-TB cases tested for resistance to second-line drugs	17

Treatment success rate and cohort size

	Success	Cohort
New and relapse cases registered in 2017	79%	2 300
Previously treated cases, excluding relapse, registered in 2017	100%	4
HIV-positive TB cases registered in 2017	81%	31
MDR/RR-TB cases started on second-line treatment in 2016	26%	19
XDR-TB cases started on second-line treatment in 2016		0

TB preventive treatment, 2018

% of HIV-positive people (newly enrolled in care) on preventive treatment	0%
% of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment	100%

TB financing, 2019

National TB budget (US\$ millions)	
------------------------------------	--

^o Ranges represent uncertainty intervals

^{oo} MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin


^{ooo} Calculated for pulmonary cases only

* Includes cases with unknown previous TB treatment history

** Includes patients diagnosed before 2018 and patients who were not laboratory-confirmed


Tuberculosis profile

(Rate per 100 000 population per year)




■ Total TB incidence
■ New and relapse TB cases notified
■ HIV-positive TB incidence

(Rate per 100 000 population per year)




■ HIV-negative TB mortality

Notified cases by age group and sex, 2018



■ Females ■ Males Incidence

Treatment success rate (%)



■ New and relapse
■ Retreatment, excluding relapse
■ HIV-positive ■ MDR/RR-TB ■ XDR-TB